As of Nov 27
| +1.00 / +15.72%|
The 2 analysts offering 12-month price forecasts for Imprimis Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 10.00 and a low estimate of 8.00. The median estimate represents a +22.28% increase from the last price of 7.36.
The current consensus among 2 polled investment analysts is to Buy stock in Imprimis Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.